1.Brenner B.M., Cooper M.E., de Zeeuw D et al. The losartan renal protection study – rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). N Engl J Med 2001; 345: 861–9.2.Cohen A, Bregman B et al. Comparison of irbesartan vs felodipine in the regression after 1 year of left ventricular hypertrophy in hypertensive patients (The SILVER trial) J Hum Hypertens 1998; 12: 479–83.3.Dahlo..f B, Devereux R et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.4.Dahlo..f B, Lindholm L.H. et al. results of the losartan versus amlodipine (LOA) study on drug tolerability and psychological general well - being J Hypertens 1997; 15: 1327–35.5.Devereux R.B., Dahlo..f B. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Curr Med Res Opin 2007; 23 (2): 443–57.6.Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high - risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002; 360: 752–60.7.Friedrich M.G., Dahlo..f B, et al. Telmisartan Effectiveness on Left ventricular MAss Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild - to - moderate hypertension – a prospective, randomised, double - blind comparison of telmisartan with metoprolol over a period of six months – rationale and study design. J Renin Angiotensin Aldosterone Syst 2003; 4: 234–43.8.Granger C.B., Mc Murray J.J..V. et al. Effects of candesartan in patients with chronic heart failure and reduced left - ventricular systolic function intolerant to angiotensin - converting - enzyme inhibitors: the CHARM-Alternative trial Lancet 2003; 362: 772–6.9.Grassi G, Seravalle G et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study J Hypertens 2003; 21: 1761–9.10.Haralambos P. Gavras, Salernob C.M. The angiotensin II Type 1 receptor blocker losartan in clinical practice: a review. Clin Ther 1996; 18 (6): 1058–67.11.Israili Z.H. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000; 14 (Suppl. 1): S73–86.12.Julius S, Kjeldsen S.E. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE. Lancet 2004; 363: 2022–31.13.Lindholm L.H., Persson M et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy. J Hypertens 2003; 21: 1563–74.14.Lithell H, Hansson L et al. The Study on Cognition and Prognosis in the Eldery (SCOPE): principal results of a randomized double - blind intervention trial J Hypertens 2003; 21: 875–86.15.Massie B.M., Carson P.E., Mc Murray J.J. et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 4: 359.16.Mc Murray J.J.V., О..stergren et al. Effects of candesartan in patients with chronic heart failure and reduced left - ventricular systolic function taking angiotensin - converting - enzyme inhibitors: the CHARM-Added trial Lancet 2003; 362: 767–71.17.Mochizuki S, Dahlo..f B et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open - label, blinded endpoint morbidity - mortality study. Lancet 2007; 369: 1431–9.18.Mogensen C.E., Neldan S et al. Randomised controlled trial of dual blockade of renin - angiotensin system in patients with hypertension, microalbuminuria, and non - insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440–4.19.Nakao N, Yoshimura A, Morita H et al. Combination treatment of angiotensin-II receptor blocker and angiotensin - converting - enzyme inhibitor in non - diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003; 361 (9352): 117–24.20.Ogihara T, Saruta T et al. Valsartan in Elderly Isolated Systolic Hypertension (VALISH) study: rationale and design. Hypertens Res 2004; 27: 657–61.21.ONTARGET Investigators Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59.22.ONTARGET/TRANSCEND Investigators Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high - risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004; 148: 52–61.23.Oparil S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am J Hypertens 2000; 13 (1 Pt 2): 18S–24S.24.Pfeffer M.A., Mc Murray J.J. et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 2003; 349: 1893–906.25.Pitt B et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747–52.26.Pitt B, Poole-Wilson P, Segal R et al. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study ELITE II. J Card Fail 1999; 5: 146–54.27.Puig J.G. et al. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertension 1999; 17: 1033–9.28.Ruilope L.M., Malacco E et al. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Clin Ther 2005; 27: 578–87.29.Saracho R, Martin-Malo A et al.Evaluation of Losartan in Hemodialysis (ELHE) study. Kidney Int 1998; 54 (Suppl. 68): S125–9.30.Schrader J, Luders S et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention. Stroke 2005; 36: 1218–26.31.Wu..rzner C et al. Comparative effects of losartan and ibresartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertension 2001; 19: 1855–60.32.Yusuf S, Pfeffer M.A. et al. Effects of candesartan in patients with chronic heart failure and preserved left - ventricular ejection fraction: the CHARM.-.Preserved trial. Lancet 2003; 362: 771–81.33.Rok Accetto, Breda Barbic€-Z€agar. SkutecznoscЂЂ hipotensyjna losartanu oraz skojarzenia losartanu z hydrochlorotiazydem u pacjentoЂw z l~agodnym lub umiarkowanym nadcisЂnieniem te`tniczym. Kardiologia po Dyplomie, 2008.